The progression to castrate resistant prostate cancer (CRPC) correlates with gain of function of the androgen receptor (AR) and activation of AKT. However, as single agents, AR or AKT inhibitors result in a reciprocal feedback loop. Therefore, we hypothesized that combination of an AKT inhibitor with an anti-androgen might result in a more profound, long lasting remission of CRPC. Here we report that the AKT inhibitor AZD5363 potently inhibits proliferation and induces apoptosis in prostate cancer cell lines expressing the androgen receptor, and has anti-cancer activity in vivo in androgen sensitive and castrate resistant phases of the LNCaP xenograft model. However, we found that the effect of on castrate resistant tumour growth inhibition and PSA stabilization is transient, and resistance occurs with rising PSA after ~ 30 days of treatment.
INTRODUCTION
While early detection and treatment of localized prostate cancer (PCa) has improved, many men still die of metastatic disease. Almost 80% of patients initially respond to androgen deprivation therapy, most patients progress to castrate resistant prostate cancer (CRPC) and metastatic disease (1) (2) (3) (4) (5) (6) . CRPC is a complex process by which cells survive and proliferate in low circulating androgen. This in part involves the re-activation of the AR axis (7), by prosurvival genes and alternative mitogenic growth factor pathways (8, 9) including the PI3K/AKT pathway which offers substantial therapeutic potential in PCa (10, 11) . This pathway is upregulated in PCa in high-risk disease and CRPC (10, 12, 13) . It has been proposed the existence of crosstalk between the PI3K/AKT pathway and the AR-axis, however the underlying molecular mechanisms still unknown (14) (15) (16) (17) (18) .
While targeting the PI3K/AKT-pathway by small molecule inhibitors has been reported to be a promising approach to delay PCa progression in the clinic (9, 17, 18) , the up-regulation of the AR-pathway seems to counter its effect in PCa (15, 16, 18) . For instance, Carver et al. showed that combined inhibition of PI3K/AKT-and AR-signaling by using the PI3K/mTOR inhibitor BEZ235 and the antiandrogen MDV3100 resulted in an enhanced antitumoral activity in the hormone-sensitive LNCaP mouse model (18) . However, it is not known whether the combined blockade of AR and PI3K/AKT pathway will effect tumor progression in the castration resistant state.
The aim of the current study is to evaluate the antitumoral activity of the novel AKT-inhibitor 
MATERIALS AND METHODS

Prostate cancer cell lines and reagents
The human PCa cell lines LNCaP and C4-2 used in this study were kindly provided by Dr.
Leland W.K. Chung (1992, MDACC, Houston TX) and tested and authenticated by wholegenome and whole-transcriptome sequencing on Illumina Genome Analyzer IIx platform in July 2009. Western blotting and/or real time PCR was performed for AR and PSA each time when LNCaP or C4-2 cells were resurrected. After resurrection, both cell lines were passaged for less than 3 months. LNCaP and C4-2 cells were maintained in RPMI 1640 medium (Invitrogen) supplemented with 5% charcoal stripped serum (CSS) or 5% fetal bovine serum (FBS) and cultured without antibiotics at 37°C in 5% CO 2 atmosphere.
Treatment of prostate cancer cells with AZD5363 and bicalutamide
The AKT-Inhibitor AZD5363 and the nonsteroidal antiandrogen bicalutamide were kindly provided from Astra Zeneca and used respectively for in vitro and in vivo. AZD5363 is a new ATP-competitive inhibitor of AKT and, as a synthetic small molecule, orally available (19, 20) .
For the in vitro studies, AZD5363 was dissolved in dimethyl sufloxide (DMSO, Sigma Aldrich, St Louis, MO) at 10mM stock solutions and stored at -20ºC. For the in vivo studies, AZD5363 was dissolved in H2O and 10% DMSO and 25% Kleptose (Roquette Pharma, France) at 100mg/ml and stored at room temperature for 1 week. For in vitro use, bicalutamide was dissolved in DMSO and stored for 4 weeks at room temperature. In vivo, bicalutamide was diluted with H 2 0 and used at 10mg/kg bodyweight.
Cell proliferation and apoptosis assays
Cell growth was assessed using crystal violet assay, as described previously (19) . Cells were plated in 96-well plates and treated with AZD5363 in FBS supplemented media. Crystal violet staining was carried out for dose-and time-dependent treatment. Cell proliferation after AZD5363 treatment was calculated as the percentage of the absorbance in untreated cells.
Caspase-3 activity was assessed 3 days after treatment using the kit CaspACE Assay System, Fluorometric (Promega, Madison, WI, USA) as we previously described (19) .
Cell cycle analysis
Changes in the different phases of cell cycle of LNCaP and C4-2 cells treated with AZD5363, bicalutamide or the combination of both were assessed by flow cytometric analysis. Cells were plated in 10 cm 2 dishes using FBS supplemented media and treated as described above. 3 days later cells were trypsinized and fixed in 70% ethanol over night at 4°C, then incubated with 1 µg/mL RNase A (Sigma) for 30min at 37ºC before stained with 5µg/mL propidium iodide (Sigma) for 30min at room temperature. The stained cells were analyzed for relative DNA content on a dual laser flow cytometer (Beckman Coulter Epics Elite; Beckman, Inc.). Each assay was done in triplicate.
Western blot analysis
Cell population was harvested in a dose-dependent manner after AZD5363 treatment at 5µM in RIPA buffer (50nM Tris, pH 7.2, 1% NP-40, 0.1% deoxycholate, 0.1% SDS, 10nM NaCl, Roche complete protease inhibitor cocktail) and Western blots were performed as we previously reported (19) using antibodies as described in Supplementary Table S1 .
Quantitative Reverse Transcription-PCR
Total RNA was extracted from cultured cells after 48h of treatment using TRIzol reagent (Invitrogen Life Technologies, Inc.). Real-time monitoring of PCR amplification of complementary DNA (cDNA) was performed as previously described (21) on ABI PRISM 7900
HT Sequence Detection System (applied Biosystems) with SYBR PCR Master Mix (Applied Biosystems). Each assay was performed in triplicate.
Luciferase assay
LNCaP and C4-2 cells were plated on 12 well plates and transfected with PSA-LuciferasePlasmid (-6,100 to +12) using lipofectin (Invitrogen Life Technologies, Inc.). The total amount of 1.0 µg per well PSA-plasmid DNA was used. 16h before start of treatment media was changed into CSS -/+ 0.1 nmol/L R1881 (PerkinElmer). Luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega) using a microplate luminometer (EG&G Berthold). Luciferase activity was normalized to the protein concentration of the cells. All experiments were carried out in triplicate wells and repeated two times.
Chromatin immunoprecipitation assay (ChIP assay)
ChIP assay was performed as previously described (22) . Briefly, LNCaP cells were cross-linked with paraformaldehyde and digested with micrococcal nuclease to achieve a DNA smear of 200-1,000 bp. ChIP assay was performed using SimpleChIP TM Enzymatic Chromatin IP Kit (Agarose Beads) according to the manufacturer's protocol (Cell Signaling Technology) on the AR gene as we previously described (21) . The results are representative of at least three independent experiments.
Assessment of synergy on cell viability
A combination-index (CI) for synergy was determined by comparing the growth inhibition of bicalutamide (range 10.0-50.0 µM) or AZD5363 (range 100.0-500.0 nM) with that of the combination of both drugs (constant ratio 1:100) based on the median effect principle (MEP).
This commonly used method was first described by Chou and Talalay (23 
Animal treatment
In vivo, we used two different animal models to mimic hormone-sensitive and castration- 
Immunohistochemistry
Immunohistochemical stains were performed on formalin-fixed and paraffin-embedded 4µm 
Statistical analysis
All results were expressed as the average + SE, and the significance of differences were measured by Student's t-test (Excel, Microsoft). p<0.05 (*), p<0.01 (**) and p<0.001 (***) were considered significant. Kaplan Meier survival analysis was performed for TPFS and CSS and statistical significance between the groups was assessed with the log-rank test (Medcalc software). 
RESULTS
AZD5363 targets the PI3K/AKT-pathway and inhibits cell proliferation
The effects of the AKT-inhibitor AZD5363 ( Table 2 ).
AZD5363 treatment induces apoptosis in PCa cells in vitro
We next evaluated the effects of AZD5363 treatment on cell apoptosis. As shown in Figure 1D , AZD5363 treatment significantly (**, p<0.01) increased the fraction of cells undergoing cell death (sub G0/G1) in a dose-dependent manner compared to control in both C4-2 and LNCaP cell lines (3.8%, 6.3%, 23.1%, 34.5% and 61.6% in LNCaP and 2.2%, 3.6%, 13.3%, 25.0% and 51.8% in C4-2 cells at 0nM, 100nM, 500nM, 1µM and 5µM AZD5363, respectively) Moreover, we found that AZD5363 induces caspase-3 activity in time dependent manner in LNCaP and C4-2 cells compared to control (Fig. 1E ) and PARP cleavage (Fig. 1F ). These results suggest that AZD5363 inhibit cell proliferation and induces apoptosis in a caspase-3 dependent manner.
AZD5363 treatment delays tumor progression to CRPC in vivo
Since AZD5363 induces apoptosis and inhibits cell proliferation in LNCaP cells, we set out to determine if AZD5363 has efficacy in vivo. We first evaluated the effect of AZD5363 in hormone 3B, PSA protein levels were higher in the control group compared to the AZD5363 treated group.
While total AKT protein was expressed uniformly in both groups, the phosphorylated isoforms AKT S473 and AKT T308 (Fig. 2D , right) were up-regulated in the AZD5363 treated animals which is in concordance with our in vitro studies (Fig. 1A) suggesting a feedback loop. However, the distal pathway biomarkers output, pS6 and Cyclin D1, were down-regulated by AZD5363 compared to control and was further confirmed by IHC analysis showing that in xenografts, pS6
was inhibited in the AZD5363 treated animals. Moreover, Ki67 as a biomarker for cell proliferation was lower in the AZD5363 arm compared to control, and cell death was greater in the AZD5363 treated tumors as shown by TUNEL staining (Fig. 2D left) .
AZD5363 treatment delays CRPC progression in vivo
We next evaluated the effect of AZD5363 on castration-resistant prostate cancer (CRPC) progression in vivo. Basically mice were castrated when PSA reached 50 to 75 ng/ml and were randomized into treatment groups when serum PSA relapsed to pre-castration levels. In Figure   on 3B ; *, p<0.05) reduced serum PSA levels and serum PSA velocity compared to control (82.8 ng/mL/week and 16.4 ng/mL/week, for vehicle and AZD5363 treated groups respectively).
Tumor progression free survival significantly (p=0.0005) improved by AZD5363 treatment compared to control. The median time to tumor progression was 14.5 days in the control group and not reached in the treatment group within the first 30 days of treatment (Fig. 3C ). In concordance with the hormone-sensitive model, AZD5363 induces a decrease of cell proliferation as measured by Ki67, increased cell death as measured by TUNEL staining and a decreased phosphorylation of S6 compared to controls (Fig. 3D) . However, after approximately 30 days, the mean tumor size and serum PSA concentration in animals treated with AZD5363 exceeded the size of the controls at the start of the experiment, indicating tumor progression and onset of resistance (Fig. 3E ). These data show that treatment benefit with AZD5363 in this model is short lived, and resistance/relapse occurs with rising PSA levels suggesting that AR is still active.
AZD5363 treatment activates the AR pathway
To explore the mechanism of treatment relapse, we evaluated the effect of AZD5363 on the AR signaling pathway. To our surprise, we found that inhibition PI3K/AKT pathway using AZD5363 increased AR expression in a time dependent manner at both mRNA and protein levels (Fig. 4A) .
Similar results were observed with PI3K/mTOR inhibitor, rapamycin ( Supplementary Fig. S3) showing increased both AR and PSA expressions at protein levels. Consistent with these data, others have found that inhibition PI3K/mTOR pathway using BEZ235 results in up-regulation of AR expression (18) . We found that AZD5363 and rapamycin also induced ERK phosphorylation ( Supplementary Fig. S3 ). This pathway may play a critical role in the cross-talk between the 
PI3K/AKT-pathway and the AR-axis. We next evaluated whether AZD5363 induces activation of AR signaling pathway. We found that AZD5363 increased AR transcriptional activity in a dosedependent manner (Fig. 4B ) associated with enhanced target genes expression at mRNA level (PSA and NKX3.1) (Fig. 4C) .To further corroborate our finding on the effect of AKT inhibition pathway on AR, we specifically down-regulated AKT using siRNA and found that AKT knockdown induced increase of PSA expression at protein level (Supplementary data Fig. S3C) supporting that targeting AKT activates the AR pathway. To further understand how targeting AKT activates AR, we performed ChIP using and found that AZD5363 increased AR binding to the AREI and ARE III sequences in PSA promoter (28) compared to control (Fig. 4D ) which was accompanied by increase AR nuclear translocation (Supplementary data Fig. S4 ), AR transcriptional activity and expression of AR target genes as we showed in Figure 4B and C.
Interestingly the effect of AZD5363 on AR activation was abrogated with the AR antagonist bicalutamide. Hence, bicatulamide abrogates AZD5363 induced AR target genes expression at mRNA and protein levels ( Fig. 4E and F ) which was associated with increase PARP cleavage (Fig. 4F) . These results suggest that combined inhibition of the AR signaling pathway using bicalutamide enhances the activity of AZD5363.
Bicalutamide synergizes with AZD5363 to inhibit cell viability and induction of apoptosis in AR-positive PCa cell lines in vitro
Since AZD5363 in combination with bicatulamide ( Fig. 5A) induced PARP cleavage, we tested if this combination has an effect on cell proliferation. As shown in Figure 5 bicalutamide to achieve a 50% decrease in cell viability was reduced by -6.2-fold in LNCaP and by -9.4-fold in C4-2 cells when AZD5363 was added (Fig. 5B) . We also found that the combination of AZD5363 + bicalutamide significantly enhanced the induction of apoptosis compared to each single agent treatment, by increasing subG1 fraction by 5 and 2-fold respectively in LNCaP and C4-2 tumor cells (Fig. 5C ) and increasing caspase 3/7 activity by 2-3-fold (Fig. 5D ).
Combination treatment of AZD5363 plus bicalutamide significantly delays CRPC tumor progression
Finally, we evaluated if combination therapy with AZD5363 and bicalutamide could result in enhanced efficacy in CRPC using LNCaP xenografts. Castrated male nude mice bearing LNCaP xenografts were randomized after PSA relapse to pre-castration level and treated either with AZD5363 100mg/kg, bicalutamide 10mg/kg or the combination of both. While AZD5363 and bicalutamide as monotherapy significantly decreased tumor growth compared to control, the combination treatment enhanced the anti-tumoral effects of each single treatment (Fig. 6A) . We found that both bicatulamide and AZD5363 slow tumor growth whereas the combination treatment significantly stopped tumor growth in all mice (Fig. 6B) . While AZD5363 and bicalutamide monotherapy decreased serum PSA levels compared to controls, the combination treatment reduced drastically PSA levels (Fig. 6C) , consequently, the combination treatment significantly prolongs the cancer-specific survival (p=0.0001) compared to control and each single drug. All mice survived during 70 days of treatment in the combination arm, whereas, 50% of mice in the AZD5363 arm and 62.5% in the bicalutamide arm were sacrificed due to high tumor burden. In the control arm, all animals were sacrificed within 57 days of treatment (Fig. 6D) . IHC analysis revealed a slightly decreased Ki67 expression in each single drug group compared to control group, whereas the combination treatment considerably diminished Ki67 (Fig. 6E) For instance, GSK690693 showed significant inhibition of tumor growth by 50% compared to control in LNCaP xenograft model (9) . The isoflavone genistein significantly reduced tumor volume and incidence in the same tumor model (17) . Furthermore, antitumoral effects of AKT inhibitors in s.c. PC3-xenograft mice have been reported in several studies (29, 32, 33) . This study shows that AKT inhibition induces a delay of tumor progression to CRPC in xenograft model. AZD5363 significantly slows down tumor growth rate and serum PSA velocity by 83.9% and 80.0%, respectively (Fig. 3A and B) . However, this effect is not long-lasting in the castration-resistant state. After 4-5 weeks treatment with AZD5363, xenograft tumors and serum PSA start to progress, demonstrating that AZD5363 as a single agent induces a tumor stabilization for some time rather than sustaining tumor regression. It has already been described in the literature that resistance to AKT-inhibitors might be induced by reactivation of the AR-axis (13) (14) (15) 17) . We demonstrate that specific pharmacologic inhibition of AKT signaling using AZD5363 induces a feedback regulation of the AR pathway (Fig. 4 A-D) . In concordance with other studies (40, 41) , we suggest that the bidirectional crosstalk between AR and AKT is a rationale for simultaneous molecular targeting of both pathways. We identified pERK as a potential link between the PI3K/AKT-pathway and the AR-axis (Supplementary Fig. 3A ) and this is due to a feed-forward loop involving activation of EGFR and IGFR ( Supplementary Fig. 3B Since Akt has been reported to phosphorylate the AR on Ser-210 and Ser-790 and inhibits its transactivation (42) and that targeting Akt phosphorylation will then result on inhibiting AR phosphorylation on Ser-210 and Ser-790, inducing AR transactivation which support our finding that targeting Akt phosphorylation with AZD5363 will abrogate AR phosphorylation and increase expression of AR dependent genes such PSA and NKx3.1 as seen in figure 4 .
To optimize the clinical response to AKT pathway inhibition, we evaluated the therapeutic effect of AZD5363 combined with AR pathway inhibition using bicalutamide. AZD5363 induced upregulation of the AR-axis which was abrogated by simultaneous treatment with antiandrogens.
In the current study, we combined AZD5363 plus bicalutamide. In vitro, AZD5363 plus bicalutamide synergized on inhibition of cell viability (Fig. 5A) . Moreover, induction of apoptosis was enhanced by combination treatment compared to each monotherapy treatment (Fig. 5 C-D) .
Notably, the addition of bicalutamide prevented AZD5363 induced up-regulation of the AR-axis (Fig. 4 E-F) .
Previous data have shown that combination treatment with anti-androgens and mTOR-inhibitors enhance anticancer activity (15, 17, 43) . However, these studies are not mimicking CRPC setting. We show here for the first time, the addition of bicalutamide significantly enhances the anti-cancer effects of AZD5363 in a CRPC xenograft model. Even after 70 days of treatment, tumor volumes in the combination arm do not exceed the values at the beginning (Fig. 6A) . Also, serum PSA levels are significantly lower in the combination arm compared to each monotreatment (Fig. 6C) . Most important, no animal in the combination arm had to be sacrificed within 70 days of treatment, whereas 50% of mice in the AZD5363 arm and 60% in the bicalutamide arm were sacrificed due to high tumor burden (Fig. 6D) . This study impressively demonstrates that the synergistic effects of AZD5363 and bicalutamide lead to long-lasting tumor remission in the castration resistant state. Moreover, it provides further evidence that 
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